Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for respiratory exacerbations in children with bronchiectasis
ACTRN12626000267358Phase 3Not yet recruiting
- Sponsor
- Queensland University of Technology
- Start
- Jul 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in bronchiectasis comparing Colchicine plus standard antibiotics with Placebo plus standard antibiotics (2 arms). Primary endpoint: Respiratory exacerbation resolution by Day 14. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
colchicine
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on ACTRN12626000267358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000267358.